All In Biotech

Free tool

FAERS Monitor: Toujeo Solostar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 206538 or its brand name (Toujeo Solostar, Insulin Glargine Recombinant). Reports on generic versions are filed under their own applications.

Reports

49,343

Serious

29,192

59% of reports

Hospitalization

16,376

Death reported

3,008

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased6,988
  • off label use2,946
  • hypoglycaemia2,605
  • drug ineffective2,286
  • product storage error1,806
  • blood glucose decreased1,787
  • nausea1,781
  • inappropriate schedule of product administration1,694
  • diarrhoea1,639
  • dyspnoea1,552
  • fatigue1,434
  • acute kidney injury1,420
  • vomiting1,393
  • hyperglycaemia1,358
  • dizziness1,322

Reports by year received

View as table
YearReports
200499
2005108
200689
2007111
2008170
2009191
2010299
2011361
2012267
2013406
2014424
20151,591
20164,212
20173,539
20185,057
20195,068
20203,858
20213,611
20223,917
20233,717
20244,203
20254,219
20263,825

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,816 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypoglycaemiaSignal2,60524.123.254,774
hyperglycaemiaSignal1,35816.515.619,006
blood glucose decreasedSignal1,78716.415.724,986
blood glucose increasedSignal6,98816.416.098,035
product storage errorSignal1,8069.08.612,549
inappropriate schedule of product administrationSignal1,6944.03.83,861
acute kidney injurySignal1,4204.03.83,163
off label use2,9461.41.4404
vomiting1,3931.31.278
dyspnoea1,5521.21.139
dizziness1,3221.11.120
diarrhoea1,6391.11.011
nausea1,7811.00.93
fatigue1,4340.80.788
drug ineffective2,2860.70.7224

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.